Disclosed is an Lck-derived peptide which is useful for the treatment or prevention of a cancer patient who is positive for an HLA-A3 supertype allele. Specifically disclosed are peptides of Lck90-99, Lck449-458 and Lck450-458 (SEQ ID NOs: 4, 17 and 18). These peptides can bind to an HLA-A3 supertype allele molecule and has a peptide-specific CTL-inducing ability. These peptides are particularly useful for the treatment of a cancer patient who is negative for an HLA-A2 or HLA-A24 molecule for which many cancer vaccine candidate peptides have been identified so far.
